Ibrutinib becomes first approved treatment for rare B-cell lymphoma

Further information
View Imbruvica drug record 
Summary of Product Characteristics
Manufacturer: Janssen Cilag

The Bruton's tyrosine kinase inhibitor ibrutinib (Imbruvica) has been approved for the treatment of patients with Waldenström's macroglobulinaemia.

Imbruvica is indicated in patients with the rare non-Hodgkin's lymphoma who have received at least one prior therapy for the condition, or as first-line treatment for patients unsuitable for chemo-immunotherapy.

Imbruvica was previously licensed only for the treatment of relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukaemia.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases